Although increasing DNA damage to decrease GBM growth is being clinically tested with TMZ and PARP inhibitor treatment (described above), the effects of TMZ and PARP inhibition on NKG2DL expression in GBM have yet to be investigated. The gene discussed is PARP1; the disease is glioblastoma.